APVO · NASDAQ
Aptevo Therapeutics (APVO) Stock Price & Fundamentals
Aptevo Therapeutics (APVO) closed at $673.23 on Oct 9, 2026, down 0.33% from the previous close of $675.44.
Share price, past year
1Y +12.41%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $673.23 |
| Sep 30, 2026 | $661.20 |
| Aug 31, 2026 | $650.71 |
| Jul 31, 2026 | $619.86 |
| Jun 30, 2026 | $619.24 |
| May 29, 2026 | $600.94 |
| Apr 30, 2026 | $655.20 |
| Mar 31, 2026 | $634.09 |
| Feb 27, 2026 | $641.55 |
| Jan 30, 2026 | $638.58 |
| Dec 31, 2025 | $618.41 |
| Nov 28, 2025 | $600.14 |
| Oct 31, 2025 | $617.47 |
Key statistics
- Market cap
- $955.28M
- P/E (TTM)
- 0.4
- EPS (TTM)
- $1,634.11
- Revenue (TTM)
- —
- Net income (TTM)
- −$26.41M
- Shares outstanding
- 1.4M
- Dividend yield
- —
- 52-week range
- $592.51 – $675.44
Aptevo Therapeutics's market cap is $955.28M, based on a share price of $673.23 and 1.4M shares outstanding as of Jun 30, 2026.
Financials
Aptevo Therapeutics reported revenue of $3.11M for fiscal 2022, down 74.67% from fiscal 2021.
Aptevo Therapeutics reported a net loss of $25.97M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2022ended Dec 31, 2022 | $3.11M | −74.7% | $8.03M | 257.8% | $58.15 | −$21.05M |
| FY2021ended Dec 31, 2021 | $12.29M | +185.3% | −$28.46M | −231.5% | −$224.81 | −$22.39M |
| FY2020ended Dec 31, 2020 | $4.31M | −86.7% | −$17.75M | −411.9% | −$193.70 | −$29.41M |
| FY2019ended Dec 31, 2019 | $32.42M | +40.6% | −$40.45M | −124.8% | −$513.33 | −$42.54M |
| FY2018ended Dec 31, 2018 | $23.07M | +57.4% | −$53.69M | −232.8% | −$88.52 | −$52.40M |
| FY2017ended Dec 31, 2017 | $14.66M | +46.8% | $6.97M | 47.6% | $12.22 | −$42.98M |
| FY2016ended Dec 31, 2016 | $9.99M | −70.3% | −$112.42M | −1,125.8% | −$205.56 | — |
| FY2015ended Dec 31, 2015 | $33.60M | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2022ended Mar 31, 2022 | $3.11M | — | — |
| Q4 FY2021ended Dec 31, 2021 | $3.67M | — | — |
| Q3 FY2021ended Sep 30, 2021 | $3.10M | — | — |
| Q2 FY2021ended Jun 30, 2021 | $3.11M | — | — |
| Q1 FY2021ended Mar 31, 2021 | $2.42M | — | — |
| Q3 FY2020ended Sep 30, 2020 | $1.46M | — | — |
| Q2 FY2020ended Jun 30, 2020 | $473.00K | — | — |
| Q4 FY2019ended Dec 31, 2019 | $9.03M | — | — |
Company profile
- Name
- Aptevo Therapeutics Inc.
- Ticker
- APVO
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 2401 4th Ave., Suite 1050, Seattle, WA 98121
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001671584
Recent SEC filings
- Sep 24, 2026
- Sep 23, 2026
- Sep 3, 2026
- Aug 21, 2026
- Aug 14, 2026
- Aug 14, 2026
- Aug 13, 2026
- Jul 27, 2026
Frequently asked questions
What is Aptevo Therapeutics's stock price?
Aptevo Therapeutics (APVO) closed at $673.23 on Oct 9, 2026, down 0.33% from the previous close of $675.44.
What is Aptevo Therapeutics's market cap?
Aptevo Therapeutics's market cap is $955.28M, based on a share price of $673.23 and 1.4M shares outstanding as of Jun 30, 2026.
How much revenue does Aptevo Therapeutics make?
Aptevo Therapeutics reported revenue of $3.11M for fiscal 2022, down 74.67% from fiscal 2021.
What is APVO's P/E ratio?
Aptevo Therapeutics's price-to-earnings ratio is 0.4, based on trailing twelve-month diluted EPS of $1,634.11.
Does Aptevo Therapeutics pay a dividend?
Aptevo Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Aptevo Therapeutics Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures